More recently, MEK1/2 inhibitors such as trametinib, cobimetinib, binimetinib, and selumetinib were shown to inhibit the growth of different NB cell lines harboring RAS-MAPK mutations [125–127]. Here, MAP2K1 is linked to neuroblastoma.